Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have b...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-07-01
|
| Series: | Clinical Pharmacology : Advances and Applications |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bioavailability-and-swallowability-of-an-age-appropriate-delayed-relea-peer-reviewed-article-CPAA |